Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

Overview of attention for article published in BMC Pulmonary Medicine, September 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (72nd percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 10 X users

Citations

dimensions_citation: 111 Dimensions

Readers on

mendeley: 123 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 14 X posts from 10 X users, with an upper bound of 26,764 followers.

Dr. Selman: El tratamiento de las PF-ILD depende del tipo de neumopatía intersticial, pero están en desarrollo ensayos de antifibróticos en PF-ILD: 👉🏾https://t.co/hfdNqwNIYm 👉🏾https://t.co/4iQ5uD4hP2 #IPF #PFILD https://t.co/9UZfmt5gKx

06 Mar 2019

Reply Repost Favourite

Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. https://t.co/BJorx82Tbn https://t.co/VBkfJhlHfl

08 Jun 2018

Reply Repost Favourite

RT @NeumoMadrid: Eficacia y seguridad d #Pirfenidona en #FibrosisPulmonar no #FPI https://t.co/gsEQOIbFjY

09 Dec 2017

Reply Repost Favourite

Eficacia y seguridad d #Pirfenidona en #FibrosisPulmonar no #FPI https://t.co/gsEQOIbFjY

08 Dec 2017

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 10 additional X posts.